Financial Performance - Corbus Pharmaceuticals reported a net loss of approximately $9.5 million for Q4 2024, compared to a net loss of $8.0 million in Q4 2023, representing a 18.75% increase in losses year-over-year[10] - For the full year 2024, the net loss was approximately $40.2 million, a decrease from a net loss of $44.6 million in 2023, indicating a 9.8% improvement[10] - Total operating expenses for the year ended December 31, 2024, were approximately $48.7 million, compared to $45.1 million in 2023, reflecting a 5.9% increase[20] Operating Expenses - Operating expenses for Q4 2024 increased by $2.5 million to approximately $12.6 million, primarily due to product development and stock-based compensation costs[11] - The weighted average number of common shares outstanding increased to 12,179,482 in 2024 from 4,423,683 in 2023, indicating a significant increase in share issuance[20] Cash and Investments - As of December 31, 2024, the company had $149 million in cash and investments, which is expected to fund operations through Q3 2027[6] Product Development - CRB-701 received Fast Track designation from the FDA for the treatment of relapsed or refractory metastatic cervical cancer, with dose optimization expected to be completed by Q4 2025[7] - The Phase 1 study for CRB-601 commenced in December 2024, with expectations to complete dose escalation by Q4 2025[9] - CRB-913, a new obesity treatment, is set to begin its first human dosing in March 2025, with a Phase 1 dose-range finding study expected to start in Q4 2025[14] - The company presented pre-clinical data showing CRB-913 is significantly more peripherally restricted than existing treatments, with a brain to plasma ratio fifty times lower than rimonabant[14]

Core Insights - Corbus Pharmaceuticals Holdings, Inc. has made significant advancements in its oncology and obesity pipeline, with promising data from its CRB-701 program and the upcoming first human dosing of CRB-913 [2][5] Corporate and Program Updates - CRB-701 is a next-generation antibody drug conjugate targeting Nectin-4, showing a promising safety profile and efficacy in advanced tumors [3][5] - CRB-913 is a highly peripherally restricted CB1 receptor inverse agonist designed for obesity treatment, demonstrating a brain to plasma ratio fifty times lower than rimonabant [4][5] - The FDA granted Fast Track designation to CRB-701 for treating metastatic cervical cancer, with ongoing studies in the U.S. and Europe [6][5] Financial Results - For Q4 2024, the company reported a net loss of approximately $9.5 million, compared to a net loss of $8.0 million in Q4 2023 [8] - The total operating expenses for Q4 2024 increased to approximately $12.6 million, primarily due to product development and stock-based compensation costs [9] - As of December 31, 2024, the company had $149.1 million in cash and investments, expected to fund operations through Q3 2027 [9]

Core Insights - Corbus Pharmaceuticals Holdings, Inc. announced participation in several upcoming investor conferences, highlighting its commitment to engaging with the investment community [1][2][3] Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [3] - The company's pipeline includes: - CRB-701: A next-generation antibody drug conjugate targeting Nectin-4 on cancer cells [3] - CRB-601: An anti-integrin monoclonal antibody that blocks TGFβ activation on cancer cells [3] - CRB-913: A peripherally restricted CB1 inverse agonist for obesity treatment [3] - Corbus is headquartered in Norwood, Massachusetts [3] Upcoming Conferences - B. Riley Securities Precision Oncology & Radiopharma Investor Conference on February 28, 2025, featuring a panel on Nectin-4 targeting therapies [2] - TD Cowen 45 Annual Health Care Conference on March 4, 2025, with a presentation scheduled [2] - Wedbush Securities Cardiometabolic Conference on March 10, 2025, focusing on alternative obesity targets [2] - Leerink Partners Global Healthcare Conference on March 12, 2025, including a presentation [3] - BMO 2025 Obesity Summit on March 25, 2025, discussing emerging technologies [3]

Core Insights - Corbus Pharmaceuticals announced the presentation of data from its first-in-human dose escalation clinical study of CRB-701 at the 2025 ASCO GU symposium [1][2] - The study focuses on a next-generation antibody-drug conjugate targeting Nectin-4 in patients with metastatic urothelial cancer and other solid tumors [3][9] Study Overview - The Phase 1 Western study enrolled participants with metastatic urothelial cancer and other solid tumors associated with Nectin-4 expression, with enrollment completed in October 2024 [3] - A total of 38 participants were enrolled, with 26 evaluable for efficacy at the December 2024 data cut [3][5] - The study mirrored the top four dose cohorts used in a concurrent China study, utilizing doses of 1.8, 2.7, 3.6, and 4.5 mg/kg [3][6] Safety and Efficacy Data - CRB-701 demonstrated a favorable safety profile, with no dose-limiting toxicities observed in either the Western or China studies [6][7] - Peripheral neuropathy rates were low, with 5% in the Western study and 3% in the China study, while skin disorders were reported at 24% in the Western study compared to 8% in the China study [7] - Clinical responses were observed in multiple tumor types, including cervical cancer and head and neck squamous cell carcinoma, with notable efficacy signals [6][8][13] Future Development - The dose optimization phase has commenced, focusing on 2.7 mg/kg and 3.6 mg/kg cohorts for various tumor types [8] - The study's findings support the continued clinical development of CRB-701, particularly for tumor types expressing Nectin-4 [8][9]

Core Insights - Corbus Pharmaceuticals announced the release of an abstract for its first-in-human dose escalation clinical study of CRB-701, which will be presented at the 2025 ASCO GU Symposium [1][2] - The study involves 31 patients as of September 2024, with updated data on 38 patients as of December 2024 to be presented [1] - The three-part Phase 1 Western study is evaluating the safety, pharmacokinetics, and efficacy of CRB-701 in patients with advanced solid tumors expressing high levels of Nectin-4 [3] Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diverse portfolio aimed at addressing serious illnesses through innovative scientific approaches [5] - The company's pipeline includes CRB-701, an antibody-drug conjugate targeting Nectin-4, CRB-601, an anti-integrin monoclonal antibody, and CRB-913, a CB1 receptor inverse agonist for obesity treatment [5] - Corbus is headquartered in Norwood, Massachusetts, and engages with the public through various social media platforms [5]

Core Insights - Corbus Pharmaceuticals announced data from its first-in-human dose escalation clinical study of CRB-701, which will be presented at the 2025 ASCO GU Symposium in San Francisco from February 13-15, 2025 [1] - The study focuses on CRB-701, a next-generation antibody-drug conjugate targeting Nectin-4 in patients with advanced solid tumors [4][5] Study Details - The Phase 1 study (NCT06265727) consists of three parts: Part A (dose escalation), Part B (dose optimization), and Part C (dose expansion) [3] - Part A evaluated four doses: 1.8 mg/kg, 2.7 mg/kg, 3.6 mg/kg, and 4.5 mg/kg administered every three weeks [3] Product Information - CRB-701 (SYS6002) is designed to target Nectin-4, a clinically validated tumor-associated antigen in urothelial cancer, using a site-specific, cleavable linker and a homogeneous drug-antibody ratio of 2 with MMAE as the payload [4] - Corbus has a diversified portfolio that includes CRB-601, an anti-integrin monoclonal antibody, and CRB-913, a CB1 receptor inverse agonist for obesity treatment [5]

Core Insights - Corbus Pharmaceuticals Holdings, Inc. will participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, with CEO Yuval Cohen presenting and attending investor meetings [1][2] Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [3] - The company's pipeline includes: - CRB-701: A next-generation antibody drug conjugate targeting Nectin-4 on cancer cells [3] - CRB-601: An anti-integrin monoclonal antibody that blocks TGFβ activation on cancer cells [3] - CRB-913: A highly peripherally restricted CB1 receptor inverse agonist for obesity treatment [3] - Corbus is headquartered in Norwood, Massachusetts [3]

Financial Performance - Corbus Pharmaceuticals reported a net loss of approximately $13.8 million for the three months ended September 30, 2024, compared to a net loss of $10.1 million for the same period in 2023, reflecting an increase in losses of about 36.6%[91]. - Total operating expenses for the three months ended September 30, 2024, were approximately $15.5 million, a 63% increase from $9.5 million in the same period of 2023[95]. - The company has an accumulated deficit of approximately $467.4 million as of September 30, 2024[91]. - Other income (expense), net for the three months ended September 30, 2024 was approximately $1.7 million in income, compared to an expense of approximately $0.6 million for the same period in 2023, reflecting a change of $2.3 million[98]. Research and Development - Research and development expenses increased to approximately $10.8 million for the three months ended September 30, 2024, up 65% from $6.6 million in the prior year, primarily due to costs associated with CRB-701 clinical trials[95]. - Research and development expenses for the nine months ended September 30, 2024 totaled approximately $23.4 million, a decrease of $0.8 million from approximately $24.2 million for the same period in 2023, primarily due to decreases in licensing costs[99]. - CRB-701 demonstrated an overall response rate of 44% and a disease control rate of 78% in metastatic urothelial cancer during clinical trials[86]. - CRB-913 is expected to enter Phase 1 studies in the first quarter of 2025, following IND-enabling studies[87]. General and Administrative Expenses - General and administrative expenses rose to approximately $4.7 million for the three months ended September 30, 2024, a 60% increase from $2.9 million in the same period of 2023[97]. - General and administrative expenses for the nine months ended September 30, 2024 totaled approximately $12.7 million, an increase of $1.9 million from approximately $10.8 million for the same period in 2023, driven by higher stock-based compensation costs[101]. Cash Flow and Financing - Net cash used in operating activities for the nine months ended September 30, 2024 was approximately $30.9 million, which includes a net loss of approximately $30.7 million[105]. - Cash used by investing activities for the nine months ended September 30, 2024 totaled approximately $130.0 million, primarily related to purchases of investments[106]. - Cash provided by financing activities for the nine months ended September 30, 2024 totaled approximately $166.6 million, related to the issuance of common stock[107]. - The company expects its cash, cash equivalents, and investments of approximately $159.4 million at September 30, 2024 will be sufficient to meet its operating and capital requirements through the third quarter of 2027[108]. - The company will need to raise significant additional capital to continue funding clinical trials for CRB-701, CRB-601, and CRB-913[109]. Debt and Agreements - The loan from K2 HealthVentures LLC was fully paid off with a final payment of $11.8 million on August 1, 2024[90]. - The CSPC License Agreement will remain effective on a Licensed Product until the expiration of the Royalty Term, which is determined by the later of the expiration of the last-to-expire Valid Claim, 10 years after the First Commercial Sale, or expiration of Regulatory Exclusivity[118]. - The Royalty Term begins from the First Commercial Sale of the Licensed Product in the country[118]. - The CSPC License Agreement may be terminated earlier for material breach, advance notice by Corbus, or upon a party's bankruptcy[118].

Financial Performance - Corbus Pharmaceuticals reported a net loss of approximately $13.8 million, or $1.15 per diluted share, for Q3 2024, compared to a net loss of approximately $10.1 million, or $2.27 per diluted share for the same period in 2023[9]. - The total operating loss for Q3 2024 was approximately $15.5 million, compared to $9.5 million in the same period in 2023[10]. - The total stockholders' equity increased to $150.5 million as of September 30, 2024, compared to a deficit of $6.9 million at the end of 2023[20]. Operating Expenses - Operating expenses increased by $6.0 million to approximately $15.5 million for Q3 2024, primarily due to a $3.2 million increase in CRB-701 clinical trial costs and higher compensation costs of $1.6 million[10]. Clinical Trials and Data - The company completed enrollment of the dose escalation part of the Phase 1 clinical trial of CRB-701, with first data expected in Q1 2025, showing a 44% overall response rate (ORR) in metastatic urothelial cancer and 43% in cervical cancer at doses ≥ 1.2 mg/Kg[4]. - CRB-913 pre-clinical data presented at Obesity Week 2024 indicated a dose-response achieving up to 38% weight loss in diet-induced obesity mice, with levels in the brain being 15-fold lower than monlunabant[6]. - The company presented promising efficacy and safety data for CRB-701 at ASCO 2024, indicating the drug is clinically active with a differentiated safety profile[2]. - CRB-601, a monoclonal antibody, is expected to dose the first patient in Q4 2024 for the treatment of advanced solid tumors[8]. Cash and Funding - As of September 30, 2024, the company had $159.4 million in cash, cash equivalents, and investments, expected to fund operations through Q3 2027[11]. - The company raised $35.6 million in net proceeds during Q3 2024 through its ATM program by issuing 663,730 shares[11].

Core Viewpoint - Corbus Pharmaceuticals Holdings, Inc. will participate in the Guggenheim Securities Healthcare Innovation Conference, highlighting its commitment to innovative treatments in oncology and obesity [1][2]. Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diversified portfolio aimed at addressing serious illnesses through innovative scientific approaches [2]. - The company's pipeline includes: - CRB-701: A next-generation antibody drug conjugate targeting Nectin-4 on cancer cells [2]. - CRB-601: An anti-integrin monoclonal antibody that blocks TGFβ activation on cancer cells [2]. - CRB-913: A peripherally restricted CB1 receptor inverse agonist for obesity treatment [2]. - Corbus is headquartered in Norwood, Massachusetts [2]. Event Details - The Guggenheim Securities Healthcare Innovation Conference will take place from November 11-13, 2024, with a specific fireside chat and one-on-one investor meetings scheduled for November 12, 2024, at 10:00 a.m. ET [1][2].